These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 30403317)

  • 21. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
    Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
    Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Tunehag KR; Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Gong Y; Kerensky RA; McDonough CW; Nguyen AB; Ortega-Paz L; Venkatesh S; Wang Y; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Cavallari LH; Lee CR
    J Am Heart Assoc; 2024 Jun; 13(12):e033791. PubMed ID: 38874073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of major adverse cardiovascular events of
    Biswas M; Kali MSK; Biswas TK; Ibrahim B
    Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
    Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the Pharmacogenomics of Antiplatelet Therapy.
    Akhtar T; Bandyopadhyay D; Ghosh RK; Aronow WS; Lavie CJ; Yadav N
    Am J Ther; 2020; 27(5):e477-e484. PubMed ID: 31498157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotype-Guided Strategy for P2Y
    Kheiri B; Simpson TF; Osman M; Kumar K; Przybylowicz R; Merrill M; Golwala H; Rahmouni H; Cigarroa JE; Zahr F
    JACC Cardiovasc Interv; 2020 Mar; 13(5):659-661. PubMed ID: 32139230
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of the
    Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
    Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel Pharmacogenetics.
    Pereira NL; Rihal CS; So DYF; Rosenberg Y; Lennon RJ; Mathew V; Goodman SG; Weinshilboum RM; Wang L; Baudhuin LM; Lerman A; Hasan A; Iturriaga E; Fu YP; Geller N; Bailey K; Farkouh ME
    Circ Cardiovasc Interv; 2019 Apr; 12(4):e007811. PubMed ID: 30998396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clopidogrel pharmacogenetics: associations between genotype and stent thrombosis risk in patients with stent placement.
    Ferrari M; Tozzi M; Marino F; Tarallo A; Riva F; Mirabile M; Castelli P; Cosentino M
    J Cardiovasc Med (Hagerstown); 2019 Jan; 20(1):46-48. PubMed ID: 30531616
    [No Abstract]   [Full Text] [Related]  

  • 30. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
    AlMukdad S; Elewa H; Al-Badriyeh D
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
    Shen DL; Wang B; Bai J; Han Q; Liu C; Huang XH; Zhang JY
    J Cardiovasc Pharmacol; 2016 Mar; 67(3):232-6. PubMed ID: 26727381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y
    Xi Z; Wang Y; Lu Q; Qiu H; Gao Y; Gao A; Gao R
    Thromb Res; 2023 Aug; 228():85-93. PubMed ID: 37301117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.
    Verma SS; Bergmeijer TO; Gong L; Reny JL; Lewis JP; Mitchell BD; Alexopoulos D; Aradi D; Altman RB; Bliden K; Bradford Y; Campo G; Chang K; Cleator JH; Déry JP; Dridi NP; Fernandez-Cadenas I; Fontana P; Gawaz M; Geisler T; Gensini GF; Giusti B; Gurbel PA; Hochholzer W; Holmvang L; Kim EY; Kim HS; Marcucci R; Montaner J; Backman JD; Pakyz RE; Roden DM; Schaeffeler E; Schwab M; Shin JG; Siller-Matula JM; Ten Berg JM; Trenk D; Valgimigli M; Wallace J; Wen MS; Kubo M; Lee MTM; Whaley R; Winter S; Klein TE; Shuldiner AR; Ritchie MD;
    Clin Pharmacol Ther; 2020 Nov; 108(5):1067-1077. PubMed ID: 32472697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2C19 pharmacogenetics in patients undergoing coronary stent placement: Is it time to test everyone?
    Price DJ; Levy MS
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):1253-1254. PubMed ID: 31172678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis.
    Biswas M; Kali SK
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1147-1159. PubMed ID: 33523336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
    Wang X; Wang S; Yang J; Yu X; Liu L
    Thromb Res; 2020 Sep; 193():130-138. PubMed ID: 32559569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention.
    Luo L; Fu M; Li Y; Chen Z; Yu J; Luo J; Hu S; Tu L; Xu X
    Clin Cardiol; 2020 Mar; 43(3):235-241. PubMed ID: 31777973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
    Zheng L; Yang C; Xiang L; Hao Z
    Biomarkers; 2019 Sep; 24(6):517-523. PubMed ID: 31215825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.